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Summary
 
The NH
 
2
 
-terminal peptide of myelin basic protein (MBP) bound to the class II major histo-
compatibility complex (MHC) protein I-A
 
u
 
 is an immunodominant epitope in experimental
autoimmune encephalomyelitis, a murine model of multiple sclerosis. However, the MBP–I-
A
 
u
 
 complex is very unstable. To investigate this, we performed site-directed mutagenesis of the
I-A
 
u
 
 MHC protein and the MBP peptide. Biochemical, T cell activation, and molecular mod-
eling studies of mutant complexes demonstrate that the MBP peptide’s key residue for MHC
binding, lysine 4, is buried in the P6 pocket of I-A
 
u
 
, which is predominantly hydrophobic.
This implies that the MBP–I-A
 
u
 
 complex differs from more stable complexes in two respects:
(
 
a
 
) the peptide leaves the NH
 
2
 
-terminal region of the MHC peptide-binding cleft unoccupied;
(
 
b
 
) the peptide is not anchored by typical favorable interactions between peptide side chains
and MHC pockets. To test these hypotheses, a modified MBP peptide was designed based on
molecular modeling, with the aim of producing strong I-A
 
u
 
 binding. Extension of the NH
 
2
 
terminus of MBP with six amino acids from the ova peptide, and replacement of the lysine side
chain in the P6 pocket with an aromatic anchor, results in 
 
.
 
1,000-fold increased binding sta-
bility. These results provide an explanation for the unusual peptide–MHC-binding kinetics of
MBP, and should facilitate an understanding of why mice are not tolerant to this self-peptide–
MHC complex.
 
X
 
-ray diffraction studies of MHC–peptide complexes
have provided a structural picture of how peptide an-
tigens are presented by the MHC (1). A striking feature of
these structures is the conservation of peptide conforma-
tion. In crystal structures of class II MHC–peptide com-
plexes (2–5), the backbone conformations of the bound
peptides are very similar, suggesting a basic pattern that
other structures may be expected to follow: an extended
peptide conformation spanning the MHC cleft from end to
end, with burial of individual sidechains (especially in the P1
and P9 pockets) resulting in stable, selective binding (1, 6).
However, some aspects of this picture may not be appli-
cable to all antigens. So far, structures have been solved
only for stable peptide–MHC complexes. Short-lived and
low-affinity complexes are also important in mediating im-
mune responses (7, 8) and in autoimmune disease (9–13).
Stable antigen–MHC complexes have dissociation half-
times of tens to hundreds of hours (14). By contrast, short-
lived complexes dissociate in minutes (9, 15, 16), suggest-
ing that their structures may be significantly different.
An interesting example is the short-lived peptide–MHC
complex involved in the murine model of multiple sclero-
sis, formed by the NH
 
2
 
-terminal fragment of mouse myelin
basic protein (MBP)
 
1
 
 and the class II MHC proteins I-A
 
u
 
or I-A
 
k
 
. This fragment of MBP binds only weakly to I-A
 
u
 
 and
I-A
 
k
 
 with a dissociation half-time of 
 
z
 
15 min from I-A
 
u
 
 and a
dissociation half-time of 
 
,
 
3 min from I-A
 
k
 
 (15). Nevertheless,
it appears to be the immunodominant epitope in the disease
model experimental autoimmune encephalomyelitis (EAE;
references 9, 17–21).
There is evidence that the NH
 
2
 
-terminal peptide of
MBP binds within the classical MHC peptide-binding
cleft. It competes for MHC binding with invariant chain
peptide (22), which has been shown to bind in the cleft of a
 
1
 
Abbreviations used in this paper: 
 
CLIP, class II–associated invariant chain
peptide; 
 
d
 
-ala, 
 
d
 
-alanine; DM, dodecyl maltoside; EAE, experimental au-
toimmune encephalomyelitis; HPSEC, high-performance size exclusion
chromatography; MBP, myelin basic protein.
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class II MHC (3). MBP also competes with other peptide
antigens such as Ova 323-339 (15, 19) and HEL 46-61
(15). MBP binding is strongly influenced by several resi-
dues (23) that have been observed to be peptide contacts in
crystal structures of MHC.
We have previously constructed molecular models of the
class II MHC alleles I-A
 
u
 
 and I-A
 
k
 
 that present the MBP
Ac1-9 peptide (23). These models did not include any anti-
genic peptide. In analyzing these models, we originally fo-
cused on two polymorphic MHC residues, 
 
b
 
38 and 
 
b
 
61,
which appeared to modulate T cell recognition of MBP in
both I-A
 
u
 
 and I-A
 
k
 
. Substitutions at these positions had
quite different effects in I-A
 
u
 
 vs. I-A
 
k
 
. Our molecular mod-
els suggested that these differences might be due to neigh-
boring polymorphisms, especially residue 
 
b
 
9 (23). This
polymorphism (histidine in K vs. valine in U) appeared to
shift surrounding sidechains significantly, and, because of its
position in an important specificity pocket (P6), also seemed
likely to create a strong difference in peptide binding selec-
tivity.
Here, we report the results of site-directed mutagenesis
of I-A residue 
 
b
 
9 and the application of these results to ob-
tain a molecular model of the MBP–I-A
 
u
 
 complex. In ad-
dition, how the model has been used to design an analogue
of MBP that binds very strongly to I-A
 
u
 
 is described.
 
Materials and Methods
 
Peptide Synthesis.
 
All peptides were synthesized using stan-
dard Fmoc chemistry and purified by reverse phase HPLC. The
identify and purity of each peptide was confirmed by a combina-
tion of analytical HPLC, amino acid analysis, and mass spectrom-
etry. For FACS
 
Ò
 
 binding assays, biotinylated peptides based on
the rat MBP sequence, MBP Ac1-13 (AcASQKRPSQRHGSK-
biotin) and mutants (K4A, K4Y, K4E) were synthesized. For
studies of the stability of isolated peptide–MHC complexes, the
following peptides and mutated variants as described in the text
were synthesized: CLIP (86-100) (KPVSQMRMATPLLMR)
and variants; mouse MBP Ac1-12 (AcASQKRPSQRSKY) and
MBP Ac1-12 K4Y (AcASQ
 
Y
 
RPSQRSKY); and ova-MBP (ISQ-
AVAASQKRPSQRSKY) and ova-MBP K4Y (ISQAVAAS-
Q
 
Y
 
RPSQRSKY) (MBP position 4 indicated in bold). A cysteine
was added to the COOH-terminal end of MBP Ac1-12 and MBP
Ac1-12 K4Y, and the free thiol side chain of the cysteine was la-
beled with 5-iodoacetamidofluorescein. All other peptides were
labeled at their NH
 
2
 
 terminus using the 
 
N
 
-hydroxysuccinimide
ester of 5,6-carboxyfluorescein (Molecular Probes, Eugene, OR).
 
Cell Cultures and Conditions.
 
Cells were grown in RPMI
1640 supplemented with 10% fetal calf serum, 2 mM glutamine,
100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 2 
 
3
 
 10
 
2
 
5
 
 M
 
b
 
-mercaptoethanol. Selection medium for the L cell transfectants
was prepared by supplementing with 100 
 
m
 
M hypoxanthine, 400
 
m
 
M aminopterin, and 16 
 
m
 
M thymidine (HAT; GIBCO BRL,
Gaithersburg, MD).
 
MHC Protein Purification.
 
Procedures for class II MHC pro-
tein isolation have been described previously (24). I-A
 
k
 
 and I-A
 
u
 
were obtained from BW5147.G.1.4 cells transfected with the ap-
propriate 
 
a
 
 and 
 
b
 
 chain cDNA (16) and purified by affinity chro-
matography on a 10-2.16 anti–I-A antibody column. Protein was
eluted with solutions of either 0.2 or 1.0 mM dodecyl maltoside
(DM)/0.5 M NaCl/0.1 M Na
 
2
 
CO
 
3
 
 pH 11.5. Protein concentra-
tions were determined using a micro BCA assay (Pierce Chemical
Co., Rockford, IL).
 
Peptide Binding to Live L Cell Transfectants.
 
Flow cytometric anal-
ysis was performed on nontransfected, wild-type, and mutated L
cell transfectants incubated with biotinylated-MBP Ac1-13 (4A,
4E, or 4Y) as described previously (23, 25)
 
. 
 
L cell transfectants (5
 
3
 
 10
 
5
 
) were washed once and incubated with 200 
 
m
 
M biotiny-
lated MBP or MBP analogue peptide in 200 
 
m
 
l final volume of
RPMI 1640 with 1% BSA for 4 h at 37
 
8
 
C, 7% CO
 
2
 
, followed by
two washes. After washing, the cells were immediately incubated
with streptavidin–Quantum red/PE conjugate (Sigma Chemical
Co., St. Louis, MO) for 20 min on ice and analyzed. FITC-con-
jugated mouse anti-A
 
b
 
k,u
 
–specific monoclonal antibody 10-2.16
(26) was used to determine the MHC expression level; these cells
were also stained for viability with propidium iodide. Samples
were analyzed on an EPICS 753 flow cytometer for dual-color
fluorescence as previously described (23). Net peptide binding
was calculated as streptavidin–Quantum red or streptavidin–phy-
coerythrin linear mean fluorescence–background linear mean flu-
orescence (nontransfected L cells plus peptide), and divided by
the FITC mean fluorescence to give the ratio of bound peptide
over the level of MHC expression. Normalized peptide binding
to the various transfectants was calculated as the ratio of net pep-
tide binding to the transfectant, divided by the net peptide bind-
ing of the MBP 4A peptide to the wild-type transfectant.
 
Peptide Dissociation Kinetics.
 
MHC protein was incubated with
excess fluorescein-labeled peptide for various times (depending
upon the time required to get the maximal amount of binding).
Excess peptide was removed from the sample with Sephadex
G50-SF spin columns pretreated with a 10 mg/ml BSA solution
to minimize the amount of nonspecific binding to the column.
The complex was isolated in a pH 5.3 sodium citrate buffer at
4
 
8
 
C, and the dissociation reaction was initiated by raising the
temperature to 37
 
8
 
C. Periodically, aliquots were taken from the
heated sample and analyzed by high performance size exclusion
chromatography (HPSEC) using a 7.5 mm 
 
3
 
 60-cm TSK
G3000SW column (Toso Haas, Montgomeryville, PA) with a
guardcolumn (7.5 
 
3
 
 75mm). Fluorescence of the peptide–MHC
complex was monitored by a Shimadzu RF-551 spectrofluoro-
metric detector and a standard UV detector connected in series
(27). The HPLC solvent was PBS/0.2 mM DM (pH 7.0) running
at room temperature at 1.0 ml/min. The protein–peptide com-
plex eluted at 
 
z
 
15 min. In the dissociation experiments where
time points were necessarily 
 
,
 
30 min apart, aliquots were taken
and placed immediately at 4
 
8
 
C. Samples were sitting on ice no
longer than 20 min before injection onto the HPSEC apparatus.
In control experiments, it was found that no significant dissocia-
tion of complex occurs in less than 10 h at 4
 
8
 
C (data not shown).
 
T Cell Stimulation Assays.
 
The MBP-specific T cell hybri-
doma BR4 was obtained from B10.BR mice as described (23).
The MBP-specific T cell clone E3 was obtained from a B10.A
mouse immunized with MBP 1–11 as described (28). For mea-
surement of T cell hybridoma IL-2 production, 4
 
 3 
 
10
 
4
 
 liters of
cell transfectants were incubated with 2
 
 3 
 
10
 
4
 
 T cell hybridoma
cells and the indicated peptide in a volume of 200 
 
m
 
l. After 18–24 h,
this mixture was frozen at 
 
2
 
80
 
8
 
C for at least 2 h before harvest-
ing supernatants, and IL-2 production was measured using the IL-
2–dependent cell line HT-2. For measurement of T cell clone
IL-3 production, 5
 
 3 
 
10
 
4
 
 I-A
 
u
 
–transfected BW5147.G.1.4 cells
were incubated with 5
 
 3 
 
10
 
4
 
 E3 clone T cells and the indicated
peptide in a volume of 200 
 
m
 
l. Supernatants were harvested at 24 h
and assayed for IL-3 production using an Endogen (Cambridge, 
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MA) ELISA assay as described by the manufacturer. MBP 4A 5A
was used as a negative control; this peptide has been found to
produce no stimulation of the MBP-specific T cells tested (data
not shown).
 
Molecular Modeling.
 
Models of the murine MHC proteins I-A
 
u
 
and I-A
 
k
 
 from previous work (23) were used as the basis for mod-
eling their complexes with the MBP Ac1-9 peptide. Peptide
backbone coordinates of the hemagglutinin 306-318 peptide,
from the crystal structure of its complex with the class II MHC
protein HLA-DR1 (29), were superimposed on our I-A
 
u
 
 and I-A
 
k
 
models, as a canonical framework for assessing different MBP-
binding modes. To model each hypothetical alignment of the
MBP Ac1-9 sequence onto the canonical peptide framework, the
MBP sidechains and MHC sidechains contacting the peptide
were predicted ab initio by self-consistent ensemble optimization
(30, 31), as previously applied to MHC modeling (23, 32).
The final MBP–MHC models were modified to refine the re-
gion surrounding a two-residue deletion in the 
 
b
 
-chain helix in
the I-A
 
u
 
 and I-A
 
k
 
 alleles at 
 
b
 
65-66. Tyr 
 
b
 
65 was rebuilt in the
context of the existing model by the program SEGMOD (33),
and the whole model refined by constrained minimization in the
program ENCAD (34), using the LOOK software suite (Molecu-
lar Applications Group, Palo Alto, CA) with default settings and
parameters.
An NH
 
2-terminally extended N-ova–MBP peptide (ISQAV-
AASQKRPSQRHG) was modeled starting from the MBP Ac1-
9–I-Au model. To construct the full NH2-terminal extension, the
crystal structure coordinates for the complex of CLIP bound to
HLA-DR3 (3) were superimposed on our model using the Cas
of the first 90 amino acids of a and b chains, and the P1 and P9
positions of the bound peptides. N-ova–MBP was based on the
first six amino acids of CLIP, plus the MBP and I-Au coordinates
of our original model, and modeled using the same procedures
and parameters as described above.
Results
Interaction of MBP Residue 4 With MHC Residue b9.
We focused initially on one MBP residue (position 4)
shown to interact strongly with I-Au (9, 21) and one MHC
residue, b9, predicted to be a key determinant of the P6
pocket (23). I-A b9 is polymorphic: it is valine in I-Au vs.
histidine in I-Ak. This suggested that b9 could create a
preference for interacting with a hydrophobic peptide
sidechain in I-Au, vs. a polar or negatively charged
sidechain in I-Ak. We synthesized an MBP Ac1-11 mutant
with peptide residue 4 lysine replaced by a negatively
charged glutamate (4E), and tested its binding to I-Ak and
I-Au by FACSÒ analysis (Fig. 1 a). This substitution im-
proves binding to I-Ak by .20-fold over wild-type, and
z2-fold over MBP Ac1-11 4A, an altered MBP peptide in
which replacement of peptide residue 4 lysine with alanine
enhances MHC affinity (17, 19). In contrast, binding to I-Au
is reduced at least 10-fold (Fig. 1 a; for comparison with
wild-type MBP Ac1-11, Tate, K.M., and P.P. Jones, un-
published results).
Evidence for a direct interaction between MBP peptide
residue 4 and I-A residue b9 is provided by studies of the
ability of site-directed mutants of b9 to bind a series of
MBP Ac1-11 peptides substituted at position 4 with ala-
nine (4A), glutamate (4E), or tyrosine (4Y). We have con-
structed a mutant of I-Au with b9 valine replaced by histi-
dine as found in I-Ak (V9H), and a mutant of I-Ak with b9
histidine replaced by valine (H9V). FACSÒ peptide binding
studies show that replacement of b9 switches the specificity
of the MHC from that characteristic of one allele to that of
the other (Fig. 1 a). Thus, although I-Ak prefers 4E and I-Au
prefers 4Y, I-Ak H9V prefers 4Y and I-Au V9H prefers 4E.
In contrast, binding of the 4A peptide is relatively insensi-
tive to these b9 substitutions (Fig. 1 a), indicating little in-
teraction between b9 and the short sidechain of MBP 4A.
The I-Au,k b9 mutants can present MBP peptides to I-Au–
and I-Ak–restricted T cells (Fig. 1 b). The pattern of T cell
stimulation by the MBP residue 4 substituted peptides mir-
rors their pattern of MHC binding (Fig. 1 a). These data
show that the specific structural complex recognized by the
T cells does contain the MBP 4–MHC b9 interaction
demonstrated by the binding data.
Structural Modeling of the MBP Ac1-9–I-Au Complex.
To assess the structural implications of the MBP 4–I-A b9
interaction, we sought to model MBP Ac1-9 bound to I-Au.
Figure 1. I-A residue b9 in-
teracts with MBP residue 4. (a)
Binding of biotinylated MBP
peptides with residue 4 lysine re-
placed with either glutamate
(4E), tyrosine (4Y), or alanine
(4A) to the surface of L cells
transfected with b9 mutants of
I-Au and I-Ak. Binding for each
mutant is compared with MBP
4A binding to wild-type I-Au
and I-Ak (normalized to 1.0 for
each allele). (b) T cell hybridoma
BR4 response to the altered
MBP peptides described above
presented by L cells transfected
with b9 mutants of I-Au and I-Ak.
T cell responses to MBP 4A were
normalized to 1.0 for each allele.1508 Binding of the NH2-terminal Peptide of Myelin Basic Protein to I-Au
Our approach is based on the most conserved feature of
MHC–peptide binding, the network of backbone hydro-
gen bonds observed in all known MHC crystal structures,
which enforces an extended conformation on the peptide
(1). This feature simplifies the problem of solving the struc-
ture of the MHC-bound peptide to determining the
“alignment” of the peptide’s sequence in the peptide-bind-
ing groove; that is, which peptide sidechains should be
placed in which MHC pockets. This strategy has been suc-
cessful in using x-ray crystallographic data obtained for the
hemagglutinin 306-318 peptide to model the structure of
an invariant chain peptide (CLIP) binding to several class II
MHCs (32), independent of x-ray crystallographic data
concerning CLIP binding (3).
We used self-consistent ensemble optimization sidechain
modeling (30, 31) to compare several possible alignments
of MBP Ac1-9 (the native peptide is acetylated on its NH2
terminus) within the peptide-binding cleft (for a detailed
description of these results, see Appendix). Most of these
modes diverge from the pattern of TCR- vs. MHC-con-
tact residues suggested by experimental studies of MBP
Ac1-9 and its analogues, suggesting that MBP 4 is unlikely
to be in any pocket other than P6. In addition to resulting
in logical MHC and TCR contacts, the placement of MBP
residue 4 in the P6 pocket results in a direct contact be-
tween MBP 4 and I-A b9, consistent with the site-directed
mutagenesis data.
Our model of MBP Ac1-9 complexed with I-Au is
shown in Fig. 2, compared with the crystal structure of he-
magglutinin 306-318 peptide complexed with HLA-DR1
(29). Based on existing class II MHC–peptide complex
crystal structures, only the first nine amino acids of MBP
could be modeled; however, the model should be applica-
ble to longer MBP peptides since they bind to I-Au in the
same registry as Ac1-9 (as shown by T cell stimulation).
Unlike known MHC–peptide structures, in which the
peptide spans the full length of the MHC cleft, MBP binds
in only part of the cleft, leaving the NH2-terminal side (as
defined by the orientation of the antigenic peptide) unoc-
cupied (Fig. 2 b). The first amino acid of the peptide lies
midway in the cleft, in the P3 position. Whereas nearly all
peptides used to study antigen presentation in vitro are
fragments from the middle of a protein sequence, and may
in vivo be presented with variable NH2- and COOH-ter-
minal extensions, MBP Ac1-9 constitutes the first nine
amino acids of the protein’s NH2 terminus.
The model also diverges from known peptide–MHC
structures by its lack of anchor residues in the deep specific-
ity-determining pockets of the cleft. In HLA-DR1, for ex-
ample, large hydrophobic sidechains near the peptide’s
NH2 and COOH termini are entirely buried in deep pock- Figure 2. Molecular model of the MBP Ac1-9–I-Au complex com-
pared with the crystal structure of a stable peptide–MHC complex. (a)
The crystal structure of a hemagglutinin (purple)-DR1 (white) complex,
with the hydrophobic anchor residues P1 (tyrosine) and P9 (leucine)
marked in red. (b) The model of MBP Ac1-9 (Ac-ASQKRPSQR, purple)
complexed with I-Au (white); the MBP 4 Lys sidechain is marked in red.
The NH2- and COOH-terminal ends of the cleft (as defined by the ori-
entation of the antigenic peptide) are indicated by letters. (c) Cross-section
side view of the MBP Ac1-9–I-Au complex, showing the empty P1
pocket (left) and general absence of anchoring interactions. The MBP
peptide backbone is shown as a ribbon (purple), with the MBP 4 Lys
sidechain in red.1509 Lee et al.
ets (P1 and P9, shown in red in Fig. 2 a). In the MBP–I-Au
model, by contrast, MBP does not even reach the P1 end
of the cleft, leaving the large P1 pocket empty. MBP places
a serine sidechain at P9, which enters the pocket only su-
perficially (Fig. 1 b). Indeed, the only substantial sidechain
buried in an MHC pocket is MBP residue 4 lysine (shown
in red in Fig. 1 b), in the largely hydrophobic P6 pocket. In
the model, the 4 lysine sidechain is deeply buried like a
typical anchor, but is unfavorable to binding because of the
cost in free energy of desolvating its charged amine group.
A longitudinal cross-section view of the MBP–I-Au model
shows the striking absence of MBP anchoring residues
from the cleft's pockets (Fig. 2 c).
The Specificity of the I-Ak,u P6 Pocket Is Consistent with
MBP Residue 4. The evidence for a direct interaction be-
tween the I-A b9 and MBP residue 4 (see first section of
Results) is an important element of our model. In our
models of class II alleles I-Ak,d,u, the b9 sidechain points to-
wards the P6 pocket (23, 32), and is predicted to contact
the MBP residue 4 sidechain there. However, the b9
mainchain atoms lie between pockets P6 and P9, and in re-
cent class II crystal structures (HLA-DR1, HLA-DR3, I-Ek)
the b9 sidechain forms one side of the P9 pocket (3, 4, 29).
To test the location of the b9 sidechain in I-Ak,u, we
have sought to relate our peptide substitution experiments
to a known crystal structure. CLIP binds to all class II
MHCs, and a crystal structure of its complex with HLA-
DR3 has been reported (3), which closely matches our
models of CLIP bound to several different MHCs includ-
ing I-Ak,u (32). We made substitutions in CLIP at the posi-
tions (residues 96, 99) found in the P6 and P9 pockets (3),
and measured their effects on binding to I-Au and I-Ak.
Our results show that I-A P6 pocket specificity, as assayed
by CLIP 96 proline ® tyrosine or proline ® glutamate
substitutions, closely matches the MBP residue 4 amino
acid preferences, whereas P9 does not. In I-Ak, glutamate is
preferred at CLIP position 96 (Fig. 3 a) whereas in I-Au ty-
rosine is preferred (Fig. 3 b). A similar pair of substitutions
at CLIP 99 (P9 position), methionine ® phenylalanine or
methionine ® glutamate produce effects unlike the MBP
residue 4 amino acid preferences (both decreased stability
of binding, see Fig. 3). Substitution studies of the CLIP res-
idues that bind in P1, P5, and P7 show no pattern of pref-
erences similar to that of P6 (36).
Design of an NH2-terminal Extension of MBP That Greatly
Stabilizes Its Binding. We have used the model to attempt
to design a variant of the MBP peptide with enhanced
binding stability. We sought to fill the NH2-terminal side
of the cleft and place a favorable anchoring sidechain (va-
line) in the P1 pocket, by adding a six amino acid sequence
(323–328) from the NH2 terminus of the ova peptide. The
model suggests several stabilizing interactions, including
three new hydrogen bonds to the peptide backbone from
I-Au residues a55–57, and burial of the valine sidechain
within the P1 pocket (Fig. 4 a).
We measured the binding and dissociation of this NH2-
terminally extended MBP peptide (ova-MBP) with I-Au
(Fig. 4 b). Ova–MBP binds with higher affinity than MBP,
and dissociates z80-fold more slowly than wild-type MBP
Ac1-12. This large increase in the stability of the complex
by addition of the six-residue NH2-terminal extension
strongly suggests that the wild-type MBP peptide does not
fill the binding groove, as shown in Fig. 2. Furthermore,
the enhanced stability of the ova–MBP complex is not due
to ova–MBP binding in a different registry from MBP, as
ova-MBP can bind to I-Au to trigger IL-3 production from
an MBP-specific T cell clone (Fig. 4 c).
To stabilize further the extended MBP peptide, we in-
troduced the substitution 4 lysine ® tyrosine (MBP residue
numbering). This mutation increases stability of binding to
Figure 3. Dissociation kinetics
of P6- and P9-substituted CLIP
peptides. Dissociation of the
wild-type CLIP 86-100 peptide
(2) and peptide analogues CLIP
96 Pro ® Tyr (filled circles), CLIP
96 Pro ® Glu (filled triangles),
CLIP 99 Met ® Phe (open cir-
cles), CLIP 99 Met ® Glu (open
triangles), and CLIP 95 Thr ®
Tyr (3) from (a) I-Ak; (b) I-Au.
The CLIP 95 tyrosine substitu-
tion is a negative control show-
ing that the stabilizing effect of
tyrosine at CLIP 96 is P6 posi-
tion specific.1510 Binding of the NH2-terminal Peptide of Myelin Basic Protein to I-Au
Figure 4. Design, dissociation kinetics, and biological activity of an NH2-terminal extension of MBP. (a) Molecular model of ova-MBP K4Y
(ISQAVAASQYRPSQRSK, shown in ball and stick) bound to I-Au (ribbon). MBP residues 1–9 are colored blue, with the NH2-terminal extension in
lighter bonds. Three hydrogen bonds from I-Au to the NH2-terminal extension are shown as dashed green lines. (b) Dissociation of the wild-type MBP
Ac1-12 (open diamonds), ova-MBP (filled diamonds), MBP Ac1-12 K4Y (open circles), and ova-MBP K4Y (filled circles) complexes with I-Au. (c) IL-3 pro-
duction of the MBP-specific E3 T cell clone in response to the following peptides presented by I-Au–transfected BW5147.G.1.4 cells: MBP Ac1-14 (open
triangles), MBP Ac1-14 K4A (inverted triangles), fluorescently-labeled ova-MBP (open squares), fluorescently labeled ova-MBP K4Y (filled squares), and neg-
ative control peptide (see Materials and Methods) MBP Ac1-14 K4A R5A (filled circles). In studies of T cell proliferation, wild-type and 4A MBP, but not
either of the extended peptides, triggered full T cell clone proliferation when presented by I-Au–expressing splenocytes (data not shown).1511 Lee et al.
I-Au for both the original MBP Ac1-11 peptide (9, 15) and
for the extended ova–MBP peptide (Fig. 4 b). This result
suggests both bind to I-Au the same way, placing residue 4
(MBP residue numbering) in the P6 pocket. Moreover, the
extended peptide is a potent activator of IL-3 production
by an MBP-specific T cell clone (Fig. 4 c), clearly indicat-
ing an identical registry as wild-type MBP. Thus, by mak-
ing two changes in MBP suggested by the model extending
its NH2 terminus and adding favorable anchor residues
(Fig. 4 a) we have increased the stability of binding to I-Au
by .1,000-fold, producing slow dissociation kinetics (t1/2
.200 h) characteristic of high affinity MHC–antigen com-
plexes.
Discussion
Evidence That the MBP Ac1-9 Peptide Binds Towards the
COOH-terminal End of the I-Au Cleft. The function of MHC
proteins is to present a diverse array of antigenic peptides to
T cells. X-ray crystallographic studies of stable peptide–
MHC complexes have shown how the MHC structure ac-
complishes this. A series of hydrogen bonds from MHC
amino acid side chains holds the peptide backbone in a
conserved extended conformation, while deep pockets in
the MHC protein accept specific peptide sidechains (espe-
cially at P1 and P9 positions; 1, 3–5). Although this design
allows stable binding of many peptides, some important an-
tigens, in particular some involved in autoimmune disease,
do not bind stably to MHC (7–13). To investigate the
structure of the short-lived peptide–MHC complex formed
by the NH2-terminal peptide of MBP bound to the class II
MHC protein I-Au, we have combined the approaches of
molecular modeling and site-directed mutagenesis. The re-
sults of these studies suggest that the MBP–I-Au complex
differs from more stable complexes in that the peptide oc-
cupies only part of the MHC–peptide-binding cleft, failing
to occupy the important P1 anchor pocket and also lacking
favorable stabilizing anchors in the other MHC pockets
(Fig. 2). Addition of either a single strong anchor (tyrosine
in the P6 pocket) or extension of the peptide to fill the P1
pocket (the designed ova–MBP peptide) greatly stabilizes
this peptide–MHC complex. Extension of the peptide
combined with addition of the strong P6 anchor results in a
greater than 1,000-fold stabilization of the complex com-
pared with the wild-type complex.
Our proposed wild-type MBP–I-Au structure does con-
tain several stabilizing interactions (Fig. 5). The MBP 4
lysine terminal amine group makes contact with two aro-
matic sidechains (b11 Phe, b30 Tyr); aromatic rings have
been shown to stabilize both charged and polar groups
(37). The model also indicates that the MBP 4 lysine amino
group may hydrogen bond to the I-Au residue b30 tyrosine
hydroxyl. It is not certain whether the MBP 4 lysine amino
group is protonated (in this connection see reference 38).
Another potential stabilization is a salt bridge between
MBP 5 Arg and I-Au b72 glutamate from the b1 helix
(Fig. 5); mutating b72 blocks binding (39). For the seven
residues of MBP that lie within the cleft there are a total of
seven backbone hydrogen bonds from I-Au, including all
the conserved hydrogen bonds observed in this region in
the HLA–DR1 complexes (2). Among these hydrogen
bonds is one from I-Au b80 asparagine (I-Au numbering) to
the MBP N-acetyl carbonyl, the only specific interaction to
the first two residues of MBP, which may be important for
positioning the NH2 terminus.
Comparison of the MBP–I-A Model with Published Data.
We have compared our model with available experimental
evidence. First, the model specifies the individual role of
each MBP sidechain in binding to the MHC and poten-
tially contacting the TCR (Fig. 6 a). Two residues are pre-
Figure 5. Interactions of MBP
Ac1-9 with I-Au. MBP Ac1-9 is
shown in skeleton bonds (thick
lines, labeled in bold); I-Au resi-
dues (thin lines) making hydrogen
bonds and a salt bridge (b72
Glu–MBP 5 Arg) to MBP are
also shown (straight dotted lines).
There is only one I-Au pocket
(P6) holding a deeply buried
MBP sidechain (dashed circle). I-Au
residues contacting MBP are in-
dicated by small labels. The
NH2- and COOH-terminal ends
of the peptide are indicated by
letters. Figure generated using
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dicted to point directly upwards towards the TCR, MBP 3
glutamine and MBP 6 proline, consistent with experimen-
tal evidence that these positions are critical for stimulation
of both Au- and Ak-restricted T cell clones (17, 19, 20, 40).
MBP 5 arginine is also predicted to be exposed at the sur-
face of the complex, and could contact the TCR. Accord-
ing to our model, it could also make a contribution to
binding, via hydrophobic burial in the P7 pocket and a salt
bridge to I-Au b72 glutamic acid. Replacement of this resi-
due by alanine reduces binding several-fold in competition
assays (19). In the model, residues 2 and 7–11 appear to
have only minor interaction with the MHC and TCR; ex-
perimentally, they can be replaced with alanine with little
effect on binding, T cell stimulation, or induction of the
MBP-mediated autoimmune disease EAE (19). Our model
indicates that the NH2-terminal acetyl group of MBP is
placed at the P2 position, a known TCR contact site.
The predicted MBP–MHC contacts (Fig. 6 b) appear
consistent with reported data on COOH-terminal trunca-
tions (21). The large reduction in binding caused by trun-
cating the peptide at residues 7 or 8, compared with the
relatively slight effect of replacing these residues with ala-
nine, indicates hydrogen bonds to the mainchain of resi-
dues 7 and 8, consistent with the model (Fig. 5). The ab-
sence of such large reductions for truncations of MBP 9–11
(21) suggests an absence of hydrogen bonding to these resi-
dues, which can be explained most directly by the place-
ment of MBP shifted towards the COOH-terminal end of
the cleft, with residues 9–11 outside the cleft.
Data on d-alanine (d-ala) substitutions in MBP (Fig. 6 b)
also appear consistent with the model. At positions 1 and 2,
d-ala does not fit Ramachandran map constraints in the
model, clashing with the adjacent carbonyl group. At posi-
tion 7 in our model, the d-ala Cb makes bad contacts with
b57 Asp and b 61 Tyr. At positions 8–11, outside the
MHC cleft, the model indicates few constraining interac-
tions disfavoring the d-amino acid. Experimentally, replac-
ing Ala 8–11 with d-ala reduces binding by only half; by
contrast, a single d-ala substitution at position 1, 2, or 7
renders binding undetectable (6).
There is also extensive data on the effects of MHC mu-
tations and polymorphisms on MBP binding (Fig. 6 c).
MBP’s asymmetric binding, which leaves the NH2-termi-
nal region of the cleft empty (see Fig. 2 b), implies that
binding of MBP Ac1-9 should be insensitive to mutations
in the NH2-terminal pockets, in agreement with experi-
mental data. For example, b86 is an important polymor-
phic position in the P1 pocket that strongly affects peptide
binding to HLA-DR (2, 42–44). I-A alleles also exhibit
significant polymorphism at this position, and peptide
binding to I-Au has been shown to be sensitive to mutation
of this residue. The substitution b86 threonine ® leucine
reduces binding of CLIP, but not of MBP (22). Similarly,
mutation of a59 ® aspartate (lysine), adjacent to the P1
and P2 peptide positions, reduces CLIP binding to I-Au,
but has no effect on MBP binding (22). According to our
model, this position is too distant from MBP to alter its
Figure 6. Comparison of the MBP Ac1-9–I-Au model with published
data. MBP sidechains pointing towards the T cell receptor (blue), interme-
diate between T cell receptor and the MHC (red), buried in an MHC
pocket (yellow), or interacting relatively little with either (green). These
features closely match the pattern of MBP interactions with TCR–MHC
as mapped by alanine-scanning substitutions (see text). Structural analysis
of d-ala substitutions and COOH-terminal deletions of MBP. MBP resi-
dues 1, 2, and 7 can not accept d-ala sterically (red spheres), while residue 8
and beyond have little constraint against d-ala (green spheres). Residue 9
and beyond (green backbone) have no mainchain hydrogen bonds to the
MHC, whereas deletion of residues 8 (orange) and 7 (red) would remove
one and two hydrogen bonds, respectively. This is in good agreement
with experimental assay of the effects of d-ala substitutions or COOH-
terminal deletions on MBP–I-Au binding (see text). Amino acid substitu-
tion sites in I-Au that have no effect on MBP binding (blue), cause dimin-
ished binding (red), or improved binding (yellow). This fits the model’s
predicted pattern of MBP–MHC interactions well (see text).1513 Lee et al.
binding. In general, the positions reported not to affect
MBP binding (blue in Fig. 6 c) in our model are distant
from the peptide.
By contrast, mutations in the COOH-terminal side of
the cleft influence MBP–peptide binding. For example,
b38 and b61 are polymorphic residues in the side and floor
of the MHC cleft, and contact MBP in the model. Muta-
tions at these sites alter MBP binding and T cell stimulation
in both I-Au and I-Ak (23). Several other positions have
been observed to influence MBP binding (39, Tate, K.M.,
unpublished results). Of these, I-Au b72 glutamate makes a
potential salt-bridge to MBP 5 arginine in the model; mu-
tating it to alanine greatly reduces binding (39). b68 argi-
nine also is close enough to interact with MBP 5 arginine;
mutating it to alanine improves binding, potentially by alle-
viating electrostatic repulsion. Overall, the positions that
affect MBP binding cluster strongly on the COOH-termi-
nal side of the cleft (red), with no effects on the NH2-ter-
minal side (Fig. 6 c). There is evidence that peptides as
short as five amino acids can bind to the class Ib MHC H2-
M3 (which has an occluded A pocket and appears to bind
peptides shifted one residue relative to class Ia MHCs; ref-
erences 46–48), or to I-Ad (49), so filling the entire binding
groove is not a prerequisite for binding to the MHC.
Implications for T Cell Selection. In the absence of excess
amounts of peptide, the rapid dissociation of MBP (half-
time of minutes; reference 15) leads to a low number of
functional MBP–I-Au complexes on the surface of antigen
presenting cells. Recent microphysiometer studies have
shown that the duration of T cell stimulation then corre-
lates with the lifetime of the peptide–MHC complexes (8).
MBP Ac1-11, which dissociates rapidly from the MHC,
produces transient T cell responses, whereas peptides that
dissociate slowly produce long-lived responses (8). Kumar
et al. (11) reported that substitutions at MBP residue 4 that
confer tight binding preferentially produce a Th1-like re-
sponse (characterized by production of IFN-g), that is not
triggered by wild-type MBP peptide and MBP variants
with similarly rapid dissociation. These results may poten-
tially be related to the observation that rapid dissociation of
TCR-MHC-antigen complexes appears to favor an antag-
onist (as opposed to agonist) response (50, 51). However,
whether short-lived peptide–MHC complexes tend to
form TCR–MHC-peptide ternary complexes of lower than
average stability is currently unknown. It has been sug-
gested that the half-time of the MBP–I-Au complex may be
too rapid for effective induction of tolerance mechanisms (9).
The placement of MBP’s NH2 terminus within the re-
gion of the cleft known to be contacted by the TCR (52)
raises questions about whether alternatively spliced tran-
scripts of MBP could affect thymic selection of MBP-respon-
sive T cell populations. MBP has been shown to be ex-
pressed as a fusion protein (with the golli polypeptide attached
to its NH2 terminus) during development, and at some
later stages, in the spleen, thymus and other tissues (53–55).
If the MBP epitope spanned the entire MHC cleft like
known antigens (2–5), the golli residues attached to its NH2
terminus in the fusion protein would be outside of the
cleft, and would likely have little effect on T cell selection.
By contrast, with the NH2 terminus of MBP placed di-
rectly in the region contacted by the T cell receptor, the
addition of golli residues during thymic selection would
likely alter T cell responses, potentially producing autore-
active T cells. We have observed that NH2-terminal exten-
sion of MBP (both ova-MBP and ova-MBP K4Y) abro-
gated proliferation responses of a series of MBP-responsive T
cell lines tested in this laboratory (Rabinowitz, J.D., un-
published data), despite allowing some IL-3 production
(Fig. 4 c). Thus, some MBP-specific T cells appear to re-
spond to the NH2-terminally extended MBP as a partial
agonist (56–58), consistent with the possibility that the
golli-MBP fusion peptide may fail to negatively select, and
instead positively select (50, 59), some MBP-responsive T
cells.
Appendix
Evaluation of Possible Registries for MBP Ac1-9 Binding
to I-Au
Models containing MBP Ac1-9 in all likely registries
were evaluated by comparison with experimental data, to
identify features of the models that were consistent versus
inconsistent with the data. The results are enumerated be-
low for each alignment model (listed according to the
MHC pocket in which the model places MBP residue 4,
the most thoroughly studied MHC contact residue of the
NH2-terminal MBP peptide). No discussion of the models
with MBP residue 4 in the P2, P5, or P8 protein pockets is
included as residues at these positions are TCR contacts
but not MHC contacts. MBP residue 4 is known to be an
important MHC contact and is not a TCR contact.
Model 1: MBP Residue 4 in MHC Pocket P1
Inconsistent. Places MBP residue 4 in P1. I-Au residue
b86 threonine in the P1 pocket is likely to disfavor large
aromatic peptide sidechains there (2, 42–44). A large aro-
matic sidechain (tyrosine) at MBP 4 greatly stabilizes MBP
binding to I-Au (9). Places MBP 5 arginine in a position
(P2) with very little interaction with the MHC. There is
evidence it has a significant interaction with I-Au (19).
Places MBP 6 proline in a position (P3) not commonly
considered a major TCR contact. Proline 6 is a key TCR
contact residue (17, 19, 20, 40). However, TCR contact
may be possible here. Places MBP 8 glutamine at P5, a ma-
jor TCR contact position. MBP 8 glutamine can be re-
placed by alanine with little effect on T cell stimulation
(19, 21). Places MBP residue 4 far from I-A residue b9.
Our site-directed mutagenesis data suggest a direct interac-
tion between these residues.
Model 2: MBP Residue 4 in MHC Pocket P3
Inconsistent. Places MBP residue 4 in P3, a relatively
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as a strong anchor position favoring a large aromatic. A
large aromatic sidechain (tyrosine) at MBP 4 greatly stabi-
lizes MBP binding to I-Au (9). Places MBP 9 arginine at
P8, a major TCR contact position. MBP 9 arginine can be
replaced by alanine with little effect on T cell stimulation
(19, 21). Places MBP 6 proline in a deep pocket (P6)
mostly inaccessible to TCR contact. MBP 6 proline is a
key TCR contact residue (17, 19, 20, 40). Places MBP res-
idue 4 far from I-A residue b9. Our site-directed mutagen-
esis data suggest a direct interaction between these residues.
Model 3: MBP Residue 4 in MHC Pocket P4
Inconsistent. Places MBP residue 4 in P4, a relatively
shallow, exposed pocket in I-Au that seems unlikely to act
as a strong anchor position favoring a large aromatic. A
large aromatic sidechain (tyrosine) at MBP 4 greatly stabi-
lizes MBP binding to I-Au (9). Places MBP 2 serine at P2
and MBP 8 glutamine at P8, known TCR contact posi-
tions. Both MBP 2 serine and MBP 8 glutamine can be re-
placed by alanine with little effect on T cell stimulation
(19, 21). Places MBP residue 4 far from I-A residue b9.
Our site-directed mutagenesis data suggest a direct interac-
tion between these residues.
Model 4: MBP Residue 4 in MHC Pocket P6
Consistent. Places MBP residue 4 in P6, a large, hydro-
phobic pocket in I-Au that has been shown to act as a
strong anchor pocket favoring a large aromatic (36). A large
aromatic sidechain (tyrosine) at MBP 4 greatly stabilizes
MBP binding to I-Au (9). Places MBP 3 glutamine at P5
and MBP 6 proline at P8, the major TCR contact posi-
tions. These residues have been shown to be major TCR
contacts in MBP Ac1-9 (17, 19, 20, 40). Places MBP resi-
due 4 in direct contact with I-A residue b9, consistent with
our b9 site-directed mutagenesis data.
Model 5: MBP Residue 4 in MHC Pocket P7
Inconsistent. Places MBP residue 4 in P7, a relatively
shallow, exposed pocket in I-Au that seems unlikely to act
as a strong anchor position favoring a large aromatic. A
large aromatic sidechain (tyrosine) at MBP 4 greatly stabi-
lizes MBP binding to I-Au (9). Places MBP 3 glutamine
buried in the P6 pocket, and MBP 6 proline buried in the
P9 pocket, where they would be relatively inaccessible to
the TCR. These residues have been shown to be major
TCR contacts in MBP Ac1-9 (17, 19, 20, 40).
Model 6: MBP Residue 4 in MHC Pocket P9
Consistent. Places MBP 4 in P9, a deep pocket that
could act as a strong anchor position favoring a large aro-
matic. A large aromatic sidechain (tyrosine) at MBP 4
greatly stabilizes MBP binding to I-Au (9). Places MBP 3
glutamine at P8, a major TCR contact position. MBP 3
glutamine is a major TCR contact (17, 19, 20, 40). Places
MBP residue 4 near to I-A residue b9. MHC residue b9
lies potentially between pockets P6 and P9, and in recent
class II crystal structures its sidechain forms one side of the
P9 pocket (3, 4, 29). The site-directed mutagenesis data
suggest a direct interaction between MBP residue 4 and I-A
residue b9.
Inconsistent. Places MBP 5 arginine and MBP 6 proline
beyond the COOH-terminal end of the peptide binding
cleft, where they are unlikely to be major TCR contacts.
Both are key TCR contact residues (17, 19, 20, 40; Tate,
K.M., and C. Beeson, unpublished data). Leaves a majority
of the peptide binding groove empty. Studies of mutated
CLIP peptides binding to I-A alleles demonstrates that I-A
residue b9 determines P6 not P9 pocket specificity.
We thank Drs. J. Goverman and E. Sercarz for bringing the golli protein to our attention. We also wish to
thank Drs. M. Davis, H. McDevitt, L. Steinman, T. Anderson, and L. Schmitt for valuable discussions and
critical reading of this manuscript.
This work was supported by the Public Health Service (National Institutes of Health grant [NIH] 5R37
AI13587-20 to H.M. McConnell, and NIH grant AI15732 to P.P. Jones). C. Lee is a postdoctoral fellow of
the American Cancer Society (grant PF-4220). M.N. Liang is supported by a Franklin Veatch Fellowship.
K.M. Tate was supported by NIH training grant AI07290. J.D. Rabinowitz is supported by the Medical Sci-
entist Training Program. C. Beeson was supported by a postdoctoral fellowship from the Cancer Research
Institute.
Address correspondence to Christopher Lee, Department of Chemistry, Stanford University, Stanford, CA
94305-5080. Phone: 650-846-3587; Fax: 650-846-3497; E-mail: leec@mag.com
Christopher Lee’s present address is Department of Chemistry & Biochemistry, University of California, Los
Angeles, Los Angeles, CA 90095. Michael N. Liang’s present address is Department of Chemistry, Harvard
University, Cambridge, MA 02138. Keri M. Tate’s present address is Anergen Inc., Redwood City, CA
94603. Craig Beeson’s present address is Department of Chemistry, University of Washington, Box 351700,
Seattle, WA 98195-1700.
Received for publication 17 November 1997 and in revised form 4 March 1998.1515 Lee et al.
References
1. Stern, L.J., and D.C. Wiley. 1994. Antigenic peptide binding
by class I and class II histocompatibility proteins. Structure. 2:
245–251.
2. Stern, L.J., J.H. Brown, T.J. Jardetzky, J.C. Gorga, R.G. Ur-
ban, J.L. Strominger, and D.C. Wiley. 1994. Crystal structure
of the human class II MHC protein HLA-DR1 complexed
with an influenza virus peptide. Nature. 368:215–221.
3. Ghosh, P., M. Amaya, E. Mellins, and D.C. Wiley. 1995.
The structure of an intermediate in class II MHC maturation:
CLIP bound to HLA-DR3. Nature. 378:457–462.
4. Fremont, D.H., W.A. Hendrickson, P. Marrack, and J. Kap-
pler. 1996. Structures of an MHC class II molecule with co-
valently bound single peptides. Science. 272:1001–1004.
5. Jardetzky, T.S., J.H. Brown, J.C. Gorga, L.J. Stern, R.G. Ur-
ban, J.L. Strominger, and D.C. Wiley. 1996. Crystallographic
analysis of endogenous peptides associated with HLA-DR1
suggests a common, polypropylene II-like conformation for
bound peptides. Proc. Natl. Acad. Sci. USA. 93:734–738.
6. Nelson, C.A., S.J. Petzold, and E.R. Unanue. 1994. Peptides
determine the lifespan of MHC class II molecules in the anti-
gen-presenting cell. Nature. 371:250–252.
7. Bertoletti, A., A. Sette, F.V. Chisari, A. Penna, M. Levrero,
M. De Carli, F. Fiaccadori, and C. Ferrari. 1994. Natural
variants of cytotoxic epitopes are T-cell receptor antagonists
for antiviral cytotoxic T cells. Nature. 369:407–410.
8. Beeson, C., J. Rabinowitz, K. Tate, I. Gutgemann, Y.-H.
Chien, P.P. Jones, M.M. Davis, and H.M. McConnell. 1996.
Early biochemical signals arise from low affinity TCR-ligand
reactions at the cell–cell interface. J. Exp. Med. 184:777–782.
9. Fairchild, P.J., R. Wildgoose, E. Atherton, S. Webb, and
D.C. Wraith. 1993. An autoantigenic T cell epitope forms
unstable complexes with class II MHC: a novel route for es-
cape from tolerance induction. Int. Immunol. 5:1151–1158.
10. Joosten, I., M.H.M. Wauben, M.C. Holewijn, K. Reske,
L.O. Pederson, C.F.P. Roosenboom, E.J. Hensen, W. van
Eden, and S. Buus. 1994. Direct binding of autoimmune dis-
ease related T cell epitopes to purified Lewis rat MHC class II
molecules. Int. Immnol. 6:751–759.
11. Kumar, V., V. Bhardwaj, L. Soares, J. Alexander, A. Sette, and
E. Sercarz. 1995. Major histocompatibility complex binding
affinity of an antigenic determinant is crucial for the differen-
tial selection of interleukin 4/5 or interferon g by T cells.
Proc. Natl. Acad. Sci. USA. 92:9510–9514.
12. Liu, G.Y., P.J. Fairchild, R.M. Smith, J.R. Prowie, D.
Kioussis, and D.C. Wraith. 1995. Low avidity recognition of
self-antigen by T cells permits escape from central tolerance.
Immunity. 3:407–415.
13. Fairchild, P.J., and D.C. Wraith. 1996. Lowering the tone:
mechanisms of immunodominance among epitopes with low
affinity for MHC. Immunol. Today. 17:80–85.
14. Rothbard, J.B., and M.L. Gefter. 1991. Interactions between
immunogenic peptides and MHC proteins. Annu. Rev. Im-
munol. 9:527–565.
15. Mason, K., D.W. Denney, Jr., and H.M. McConnell. 1995.
Myelin basic protein peptide complexes with the class II
MHC molecules I-Au and I-Ak form and dissociate rapidly at
neutral pH. J. Immunol. 154:5216–5227.
16. Mason, K., D.W. Denney, Jr., and H.M. McConnell. 1995.
Kinetics of the reaction of a myelin basic protein peptide
with soluble IAu. Biochemistry. 34:14874–14878.
17. Wraith, D.C., D.E. Smilek, D.J. Mitchell, L. Steinman, and
H.O. McDevitt. 1989. Antigen recognition in autoimmune
encephalomyelitis and the potential for peptide-mediated im-
munotherapy. Cell. 59:247–255.
18. Smilek, D.E., D.C. Wraith, S. Hodgkinson, S. Dwivedy, L.
Steinman, and H.O. McDevitt. 1991. A single amino acid
change in a myelin basic protein peptide confers the capacity
to prevent rather than induce experimental autoimmune en-
cephalomyelitis. Proc. Natl. Acad. Sci. USA. 88:9633–9637.
19. Gautam, A.M., C.I. Pearson, D.E. Smilek, L. Steinman, and
H.O. McDevitt. 1992. A polyalanine peptide with only five
native myelin basic protein residues induces autoimmune en-
cephalomyelitis. J. Exp. Med. 176:605–609.
20. Wraith, D.C., B. Bruun, and P.J. Fairchild. 1992. Cross-reac-
tive antigen recognition by an encephalitogenic T cell recep-
tor. Implications for T cell biology and autoimmunity. J. Im-
munol. 149:3765–3770.
21. Gautam, A.M., C.B. Lock, D.E. Smilek, C.I. Pearson, L.
Steinman, and H.O. McDevitt. 1994. Minimum structural
requirements for peptide presentation by major histocompat-
ibility complex class II molecules: implications in induction
of autoimmunity. Proc. Natl. Acad. Sci. USA. 91:767–771.
22. Gautam, A.M., C. Pearson, V. Quinn, H.O. McDevitt, and
P.J. Milburn. 1995. Binding of an invariant-chain peptide,
CLIP, to I-A major histocompatibility complex class II mole-
cules. Proc. Natl. Acad. Sci. USA. 92:335–339.
23. Tate, K.M., C. Lee, S. Edelman, C. Carswell-Crumpton, R.
Liblau, and P.P. Jones. 1995. Interactions among polymor-
phic and conserved residues in MHC class II proteins affect
MHC:peptide conformation and T cell recognition. Int. Im-
munol. 7:747–761.
24. Watts, T.H., A.A. Brian, J.W. Kappler, P. Marrack, and
H.M. McConnell. 1984. Antigen presentation by supported
planar membranes containing affinity-purified I-Ad. Proc.
Natl. Acad. Sci. USA. 81:7564–7568.
25. Busch, R., G. Strang, K. Howland, and J. Rothbard. 1990.
Degenerate binding of immunogenic peptides to HLA-DR
proteins on B cell surfaces. Int. Immunol. 2:443–451.
26. Oi, V.T., P.P. Jones, L.A. Herzenberg, and L.A. Herzenberg.
1978. Properties of monoclonal antibodies to mouse Ig allo-
types, H-2, and Ia antigens. Curr. Top. Microbiol. Immunol. 81:
115–129.
27. Witt, S.N., and H.M. McConnell. 1991. A first-order reac-
tion controls the binding of antigenic peptides to major histo-
compatibility complex class II molecules. Proc. Natl. Acad.
Sci. USA. 88:8164–8168.
28. Rabinowitz, J.D., K. Tate, C. Lee, C. Beeson, and H.M.
McConnell. 1997. Specific T cell recognition of kinetic iso-
mers in the binding of peptide to class II major histocompati-
bility complex. Proc. Natl. Acad. Sci. USA. 94:8702–8707.
29. Brown, J.H., T.S. Jardetzky, J.C. Gorga, L.J. Stern, R.G. Urban,
J.L. Strominger, and D.C. Wiley. 1993. The three-dimen-
sional structure of the human class II histocompatibility anti-
gen HLA-DR1. Nature. 364:33–39.
30. Lee, C., and S. Subbiah. 1991. Prediction of protein side-
chain conformation by packing optimization. J. Mol. Biol.
217:373–388.
31. Lee, C. 1994. Predicting protein mutant energetics by self-
consistent ensemble optimization. J. Mol. Biol. 236:918–939.
32. Lee, C., and H.M. McConnell. 1995. A general model of in-
variant chain association with class II major histocompatibility
complex proteins. Proc. Natl. Acad. Sci. USA. 92:8269–8273.
33. Levitt, M. 1992. Accurate modeling of protein conformation
by automatic segment matching. J. Mol. Biol. 226:507–533.1516 Binding of the NH2-terminal Peptide of Myelin Basic Protein to I-Au
34. Levitt, M. 1983. Molecular dynamics of native protein: com-
puter simulation of trajectories. J. Mol. Biol. 168:595–620.
35. Deleted in proof.
36. Liang, M.N., C. Lee, Y. Xia, and H.M. McConnell. 1996.
Molecular modeling and design of invariant chain peptides
with altered dissociation kinetics from class II MHC. Biochem-
istry. 35:14734–14742.
37. Dougherty, D.A. 1996. Cation-p interactions in chemistry
and biology: a new view of benzene, Phe, Tyr and Trp. Sci-
ence. 271:163–168.
38. Stites, W.E., A.G. Gittis, E.E. Lattman, and D. Shortle. 1991.
In a staphylococcal nuclease mutant the side-chain of a lysine
replacing valine 66 is fully buried in the hydrophobic core. J.
Mol. Biol. 221:7–14.
39. Pearson, C.I. 1994. An analysis of peptide, MHC, and T cell
receptor trimolecular complexes in experimental autoim-
mune encephalomyelitis (encephalomyelitis). Ph.D. thesis.
Stanford University, Stanford, CA. 144 pp.
40. Davis, C.B., D.J. Mitchell, D.C. Wraith, J.A. Todd, S.S.
Zamvil, H.O. McDevitt, L. Steinman, and P.P. Jones. 1989.
Polymorphic residues on the I-Ab chain modulate the stimu-
lation of T cell clones specific for the N-terminal peptide of
the autoantigen myelin basic protein. J. Immunol. 143:2083–
2093.
41. Mason, K. 1995. Interactions of antigenic peptides with class
II major histocompatibility molecules. Ph.D. thesis. Stanford
University, Stanford, CA. 102 pp.
42. Busch, R., C.M. Hill, J.D. Hayball, J.R. Lamb, and J.B.
Rothbard. 1991. Effect of natural polymorphism at residue
86 of the HLA-DR b chain on peptide binding. J. Immunol.
147:1292–1298.
43. Demotz, S., C. Barbey, G. Corradin, A. Amoroso, and A.
Lanzavecchia. 1993. The set of naturally processed peptides
displayed by DR molecules is tuned by polymorphism of res-
idue 86. Eur. J. Immunol. 23:425–432.
44. Newton-Nash, D.K., and D.D. Eckels. 1993. Differential ef-
fect of polymorphism at HLA-DR1 b-chain positions 85 and
86 on binding and recognition of DR1-restricted antigenic
peptides. J. Immunol. 150:1813–1821.
45. Deleted in proof.
46. Gulden, P.H., P.I. Fischer, V.H. Engelhard, J. Shabanowitz,
D.F. Hunt, and E.G. Pamer. 1996. A Listeria monocytogenes
pentapeptide is presented to cytolytic T lymphocytes by the
H2-M3 MHC class Ib molecule. Immunity. 5:73–79.
47. Lenz, L.L., B. Dere, and M.J. Bevan. 1996. Identification of
an H2-M3-restricted Listeria epitope: implications for anti-
gen presentation by M3. Immunity. 5:63–72.
48. Lindahl, K.F., D.E. Byers, V.M. Dabhi, R. Hovik, E.P.
Jones, G.P. Smith, C.R. Wang, H. Xiao, and M. Yoshino.
1997. H2-M3, a full-service class Ib histocompatibility anti-
gen. Annu. Rev. Immunol. 15:851–879.
49. Dornmair, K., B.R. Clark, and H.M. McConnell. 1991.
Binding of truncated peptides to the MHC molecule IAd.
FEBS Lett. 294:244–246.
50. Alam, S.M., P.J. Travers, J.L. Wung, W. Nasholds, S. Red-
path, S.C. Jameson, and N.R.J. Gascoigne. 1996. T-cell-recep-
tor affinity and thymocyte positive selection. Nature. 381:
616–620.
51. Lyons, D.S., S.A. Lieberman, J. Hampl, J.J. Boniface, Y.
Chien, L.J. Berg, and M.M. Davis. 1996. A TCR binds to
antagonist ligands with lower affinities and faster dissociation
rates than to agonists. Immunity. 5:53–61.
52. Garcia, K.C., M. Degano, R.L. Stanfield, A. Brunmark,
M.R. Jackson, P.A. Peterson, L. Teyton, and I.A. Wilson.
1996. An ab T cell receptor structure at 2.5 A and its orien-
tation in the TCR-MHC complex. Science. 274:209–219.
53. Pribyl, T.M., C.W. Campagnoni, K. Kampf, T. Kashima,
V.W. Handley, J. McMahon, and A.T. Campagnoni. 1993.
The human myelin basic protein gene is included within a
179-kilobase transcription unit: expression in the immune
and central nervous systems. Proc. Natl. Acad. Sci. USA. 90:
10695–10699.
54. Fritz, R.B., and I. Kalvakolanu. 1995. Thymic expression of
the golli-myelin basic protein gene in the SJL/J mouse. J.
Neuroimmunol. 57:93–99.
55. Landry, C.F., J.A. Ellison, T.M. Pribyl, C. Campagnoni, K.
Kampf, and A.T. Campagnoni. 1996. Myelin basic protein
gene expression in neurons: developmental and regional
changes in protein targeting within neuronal nuclei, cell bod-
ies, and processes. J. Neurosci. 16:2452–2462.
56. Evavold, B.D., and P.M. Allen. 1991. Separation of IL-4
production from Th cell proliferation by an altered T cell re-
ceptor ligand. Science. 252:1308–1310.
57. Racioppi, L., F. Ronchese, L.A. Matis, and R.N. Germain.
1993. Peptide-major histocompatibility complex class II
complexes with mixed agonist/antagonist properties provide
evidence for ligand-related differences in T cell receptor-
dependent intracellular signaling. J. Exp. Med. 177:1047–1060.
58. Kersh, G.J., and P.M. Allen. 1996. Essential flexibility in the
T-cell recognition of antigen. Nature. 380:495–498.
59. Margulies, D.H. 1996. An affinity for learning. Nature. 381:
558–559.